AlloVir, Inc.

NasdaqCM:ALVR Voorraadrapport

Marktkapitalisatie: US$62.9m

AlloVir Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

AlloVir heeft een totaal eigen vermogen van $121.1M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $122.5M en $1.4M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$121.85m
AandelenUS$121.12m
Totaal verplichtingenUS$1.41m
Totaal activaUS$122.53m

Recente financiële gezondheidsupdates

Recent updates

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Feb 09
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Oct 03
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Jun 23
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Mar 02
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Nov 11
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir GAAP EPS of $0.69 beats by $1.42

Aug 04

AlloVir stock surges on $126.6M securities offering

Jul 27

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Jul 27
Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21
Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02
We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06
AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01
AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07
This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08
Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.28

Nov 10

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $122.5M ) ALVR } overtreffen de korte termijn passiva ( $1.4M ).

Langlopende schulden: ALVR heeft geen langlopende schulden.


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ALVR is schuldenvrij.

Schuld verminderen: ALVR heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 9.1% was.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ALVR heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: ALVR heeft voldoende kasruimte voor 1.1 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 25.2 % per jaar.


Ontdek gezonde bedrijven